Latest Breaking News On - Pathogenesis program at sanford burnham prebys - Page 2 : comparemela.com
Model Medicines announces AI-driven drug discovery partnership with Sanford Burnham Prebys
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Model Medicines announces AI-driven drug discovery partnership with Sanford Burnham Prebys
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Sumit Chanda, co-senior study author and director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys. view more
Credit: Sanford Burnham Prebys Medical Discovery Institute
LA JOLLA, CALIF. - March 16, 2021 - A
Nature study authored by scientists at Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong shows that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization s List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19. Based on these findings, a Phase 2 study evaluating clofazimine as an at-home treatment for COVID-19 could begin immediately.
Leprosy drug holds promise as at-home treatment for COVID-19
scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.
The virus SARS-CoV-2, which causes COVID-19.
Sanford Burnham Prebys Medical Discovery Institute
Senior study author Sumit Chanda, Ph.D., director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys. Previous Next
Newswise LA JOLLA, CALIF. – Jan 12, 2020 – Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified the sensor in human lungs that detects SARS-CoV-2 and signals that it’s time to mount an antiviral response. The study, published today in
Cell Reports, provides insights into the molecular basis of severe disease and may enable new strategies for the treatment and prevention of COVID-19.
“Our research has shown that MDA-5 is the immune cop that’s tasked to keep an eye out for SARS-CoV-2 and call for back-up,” says Sumit Chanda, Ph.D., director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys and senior author of the study. “MDA-5 recognizes replicating viruses in lung cells and activate